Siemens Healthineers has introduced two new assays for quick diagnosis of acute myocardial infarction or heart attack, following approval from the US Food and Drug Administration (FDA).

The High-Sensitivity Troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in-vitro diagnostic analysers are designed to detect low cardiac troponin I levels in serum or plasma.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Said to demonstrate 99% precision, the assays can also identify small changes in a patient’s troponin level because of repeat testing.

“According to Siemens, the TnIH assays leverage the company’s technology with three new monoclonal antibodies and are set to provide better patient care with high-sensitivity cardiac troponin detection.”

Early diagnosis is critical as the heart muscle starts dying within 30-60 minutes following the blockage of blood flow to the heart.

Since dying heart muscle releases troponin into the bloodstream, the compound is considered as an indicator of a heart attack.

Out of the more than eight million visits to emergency departments in the US, only 5.5% lead to serious diagnoses such as heart attacks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new assays are expected to support testing initiatives by using data to correctly triage patients early or rule out myocardial infarctions.

Zuckerberg San Francisco General Hospital and Trauma Center, Clinical Chemistry and Toxicology chief Alan Wu said: “If we can do a more efficient job at triaging patients to receive the proper level of care and to discharge the patients who do not need to stay in the emergency department, this will have a tremendous economic advantage for our healthcare system.”

According to Siemens, the TnIH assays leverage the company’s technology with three new monoclonal antibodies and are set to provide better patient care with high-sensitivity cardiac troponin detection.

The Siemens portfolio for troponin detection additionally includes Atellica IM, ADVIA Centaur, Dimension EXL and Dimension Vista TNIH assays that are also designed to detect lower troponin levels.